asenapine has been researched along with Basal Ganglia Diseases in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hundt, C; Kelly, L; Landbloom, R; Mackle, M; Mathews, M; McIntyre, RS; Snow-Adami, L; Wu, X | 1 |
| de Greef, R; Maloney, A; Olsson-Gisleskog, P; Panagides, J; Schoemaker, J | 1 |
| Alphs, L; Buchanan, RW; Cazorla, P; den Hollander, W; Ha, X; Kouassi, A; Panagides, J; Phiri, P; Schooler, N; Szegedi, A; Zhao, J | 1 |
| Emsley, R; Naber, D; Panagides, J; Schoemaker, J; Stet, L; Vrijland, P | 1 |
3 trial(s) available for asenapine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dibenzocycloheptenes; Disease Progression; Disorders of Excessive Somnolence; Dizziness; Double-Blind Method; Dysgeusia; Europe; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Hypesthesia; Least-Squares Analysis; Male; Mouth Diseases; Olanzapine; Schizophrenia; Schizophrenic Psychology; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Weight Gain | 2017 |
Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia.
Topics: Adult; Affect; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dibenzocycloheptenes; Double-Blind Method; Drug Resistance; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Interpersonal Relations; Male; Middle Aged; Olanzapine; Psychiatric Status Rating Scales; Psychometrics; Psychomotor Performance; Schizophrenia; Schizophrenic Psychology; Social Behavior; Young Adult | 2012 |
Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comparative Effectiveness Research; Diagnostic and Statistical Manual of Mental Disorders; Dibenzocycloheptenes; Dose-Response Relationship, Drug; Drug Monitoring; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Longitudinal Studies; Male; Middle Aged; Olanzapine; Pharmacovigilance; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Time; Treatment Outcome; Weight Gain | 2012 |
1 other study(ies) available for asenapine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms.
Topics: Algorithms; Antipsychotic Agents; Basal Ganglia Diseases; Biological Availability; Biomarkers; Computer Simulation; Dibenzocycloheptenes; Dose-Response Relationship, Drug; Endpoint Determination; Heterocyclic Compounds, 4 or More Rings; Humans; Models, Statistical; Positron-Emission Tomography; Psychiatric Status Rating Scales; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Tomography, Emission-Computed, Single-Photon | 2011 |